Add BrightSurf on Google Email

City of Hope scientists develop universal donor stem cell therapy to treat degenerative brain diseases in a preclinical study

Researchers at City of Hope have developed a universal donor stem cell therapy that can treat degenerative brain diseases such as Canavan disease and Alzheimer's. The therapy, which uses an 'off-the-shelf' approach, has shown promising results in preclinical studies, reducing toxic accumulation of metabolites and improving motor function.

SourceCity of Hope·JournalAdvanced Science·TypeExperimental study·DateJun 15, 2023

Purified pituitary tissue generated from stem cells

Scientists have successfully converted human pluripotent stem cells into purified pituitary cells that secrete adrenocorticotropic hormone (ACTH), a hormone normally produced by the pituitary gland. Transplantation of these cells into mice with hypopituitarism resulted in long-lasting improvement in ACTH levels.

SourceCell Press·JournalStem Cell Reports·TypeExperimental study·DateJun 8, 2023

Coaxing hair growth in aging hair follicle stem cells

Researchers at Northwestern University have discovered a way to soften stiff hair follicle stem cells, enabling them to grow hair again. By boosting the production of microRNA-205, they promote hair growth in both young and old mice, offering potential for human hair regrowth.

SourceNorthwestern University·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateJun 5, 2023

Parkinson’s disease drug ropinirole safely slowed the progression of ALS for over 6 months in a clinical trial

Researchers found that ropinirole is safe and effective in slowing ALS progression, with patients showing improved physical activity and muscle strength after treatment. The study suggests that the method of growing motor neurons from patient-derived stem cells could be used to predict a patient's response to the drug.

SourceCell Press·JournalCell Stem Cell·TypeExperimental study·DateJun 1, 2023

Gene engineered cell therapy developed to target brain metastatic melanomas

Scientists from Brigham and Women's Hospital have developed a new immuno-therapeutic approach using twin stem cells that can target brain metastatic melanomas. The therapy, which uses an engineered 'twin stem cell model,' activates the immune system to suppress tumor growth and prolong survival in representative preclinical models.

SourceBrigham and Women's Hospital·JournalScience Translational Medicine·TypeExperimental study·DateMay 31, 2023

Researchers overcome stem cell delivery barrier, paving the way for regenerative medicine

Scientists have developed a new method to deliver genetic information to stem cells using nanoparticles coated with a specific polymer, enabling more efficient control over cellular differentiation. This innovation has the potential to improve the efficiency and effectiveness of regenerative medicine treatments.

SourceXi'an Jiaotong-Liverpool University·JournalNano Letters·TypeExperimental study·DateMay 8, 2023

Study: ChemoID platform-predicted treatments lead to longer survival for glioblastoma patients

A multi-institutional phase 3 clinical trial found that a cancer stem cell test can accurately decide more effective treatments and lead to increased survival for patients with recurrent glioblastoma. ChemoID, a CLIA-accredited diagnostic test, was used to select chemotherapy treatments, resulting in significantly lower risk of death a...

SourceUniversity of Cincinnati·JournalCell Reports Medicine·TypeRandomized controlled/clinical trial·DateMay 5, 2023

Organoids validated as tool for studying fetal intestine development

Cincinnati Children's scientists have successfully grown functional human intestinal organoids that mimic key development stages of the human fetus. These lab-grown tissues accurately replicate the formation of specific cell types and tissue structures, providing a valuable resource for studying fetal intestine development and potentia...

SourceCincinnati Children's Hospital Medical Center·JournalDevelopment·TypeExperimental study·DateMay 4, 2023

Differentiation landscape of acute myeloid leukemia charted with new tool

A new method, CloneTracer, distinguishes between cancerous and healthy stem cells in acute myeloid leukemia (AML). The study reveals two distinct stem cell compartments and shows that progenitor cells respond better to therapy. This finding paves the way for developing new techniques to predict patient response to chemotherapy.

SourceCenter for Genomic Regulation·JournalCell Stem Cell·TypeExperimental study·DateApr 24, 2023

Scientists create powerful, most-accurate tools to research deadliest blood cancer, study says

Researchers at The Mount Sinai Hospital have created versatile disease models of acute myeloid leukemia (AML), allowing for accurate study of the cancer's progression and response to drugs. These models, derived from induced pluripotent stem cells, can mimic different stages of AML and are nearly identical to those found in patients.

Healing the unhealable: New approach helps bones mend themselves

Researchers developed a novel approach that promotes bone regeneration in mice without implantation of bone tissue or biomaterials. By carefully stretching the skull along its sutures, they activated skeletal stem cells that reside in these wiggly seams, repairing damage to the skull that would not have healed on its own.

SourceUniversity of Pittsburgh·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateApr 14, 2023

Two-organ chip to answer fatty liver questions

Researchers created the integrated-gut-liver-on-a-chip platform to examine how gut and liver cells interact, particularly in relation to non-alcoholic fatty liver disease. The study showed significant changes in gene expression and DNA damage when free fatty acids were introduced, leading to cell death similar to severe cases of NAFLD.

SourceKyoto University·JournalCommunications Biology·TypeExperimental study·DateApr 7, 2023

“We were dancing around the lab” – cellular identity discovery has potential to impact cancer treatments

Researchers at Trinity College Dublin have discovered a new process that explains why cells have unique identities. By studying Polycomb protein complexes, the team found that different forms of these proteins recruit distinct complexes to DNA, shedding light on cellular identity and its potential impact on cancer treatments.

SourceTrinity College Dublin·JournalMolecular Cell·DateApr 7, 2023

Why does a leukemic mutation not always lead to leukemia? A new clue from a mouse study at USC

Scientists from USC Stem Cell laboratory discovered a mechanism linking leukemic mutations to varying disease potentials, identifying RNA splicing regulator Rbm25 as a critical factor. The study found that over-contributing clones of blood stem cells produce excessive myeloid cells, leading to potential leukemia development.

SourceKeck School of Medicine of USC·JournalBlood·TypeExperimental study·DateMar 23, 2023

Patient-specific cells generated from thymus organoids

The study successfully generated functional patient-specific T-cells and thymic epithelial cells from human pluripotent stem cells using thymus organoids. This breakthrough provides a new experimental model system to investigate thymic insufficiency and function, potentially leading to cell-based treatments for thymic defects.

SourceCell Press·JournalStem Cell Reports·TypeExperimental study·DateMar 23, 2023

Potential relief for osteoarthritis moves to clinical trial after animal studies

Researchers have found a potential treatment for osteoarthritis by targeting the GP130 immune receptor, which causes hyper-inflammation in joints. The new compound R805/CX-011 showed promising results in animal studies, reducing joint pain and stiffness, and may lead to Phase 1 and 2A clinical trials.

SourceKeck School of Medicine of USC·JournalScience Translational Medicine·TypeExperimental study·DateMar 22, 2023

UCLA-led study uses base editing to correct mutation that causes rare immune deficiency

Researchers at UCLA successfully used base editing to correct a mutation causing rare immune deficiency CD3 delta SCID. The treatment corrected an average of 71% of patient stem cells and allowed them to produce fully functional T cells, suggesting long-term persistence of corrected blood stem cells.

SourceUniversity of California - Los Angeles Health Sciences·JournalCell·TypeExperimental study·DateMar 20, 2023

Marker for therapy response in acute myeloid leukemia (AML) identified

Researchers at German Cancer Research Center have developed a marker that predicts which patients with acute myeloid leukemia (AML) will respond to the new therapy. The marker, known as the MAC score, measures the ratio of specific proteins in leukemia stem cells and can be used to determine treatment success.

Attracting stem cells and facilitating bone regeneration by adhesive protein

A new coating material developed by Korean researchers facilitates bone regeneration and attracts osteo-progenitor cells, significantly improving the success rate of dental implants. The coating, loaded with BMP-2, prevents non-osteogenic cell invasion and induces high bone differentiation in a short period.

SourcePohang University of Science & Technology (POSTECH)·JournalBioengineering & Translational Medicine·DateMar 13, 2023